EQT Life Sciences

Activity from announced rounds

Activity in this selectionJan 31, 2026 · Jan 1, 2026
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$397.8M
3 disclosed · full round size, not this investor’s share

By stage

Series B3

By primary sector

Biotech3

By country

United States2
Germany1

Rounds

3 in this selection
Exciva

Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease

€51MSeries B
Role not disclosed